Evidence map›Paper›PMID 34799768›Full record

ArticleDigestive diseases and sciences2022

Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis.

Tien S Dong, Jonathan P Jacobs, Vatche Agopian, Joseph R Pisegna, Walid Ayoub, Francisco Durazo, Pedram Enayati, Vinay Sundaram, Jihane N Benhammou, Mazen Noureddin and 6 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. [Research advances of metabolomics in early diagnosis of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Tien S DongThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jonathan P JacobsThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Vatche AgopianDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Joseph R PisegnaDivision of Gastroenterology, Hepatology and Parenteral Nutrition, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Walid AyoubDivision of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Francisco DurazoFroedtert Hospital Transplant Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Pedram EnayatiDivision of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vinay SundaramDivision of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jihane N BenhammouThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Mazen NoureddinDivision of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Gina ChoiThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Venu LagishettyThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Oliver FiehnWest Coast Metabolomics Center, University of California, Davis, CA, USA.
Marc T GoodmanCedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
David ElashoffDepartment of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA.
Shehnaz K HussainDepartment of Public Health Sciences, School of Medicine and Comprehensive Cancer Center, University of California, Davis, Medical Sciences 1C, One Shields Avenue, Davis, CA, 95616, USA. skhussain@ucdavis.edu.ORCID 0000-0002-2015-0546
University of California, Los Angeles · USCedars-Sinai Medical Center · USUniversity of California, Davis · USFroedtert Hospital · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
GASTROENTEROLOGYT32DK007180 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JENSEN, DENNIS MICHAEL · 1986 to 2025
$10.0M
Gut-Related Markers and Hepatocellular Cancer in a Multi-Ethnic Cirrhotic CohortR01CA204145 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HUSSAIN, SHEHNAZ KHURSHEED · 2016 to 2020
$1.8M
Modulation of the Intestinal Microbiome in Obesity by a High Protein DietIK2CX001717 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI JACOBS, JONATHAN PATRICK · 2018 to 2023
–
CSRD VA IK2 CX001717NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA204145NIDDK NIH HHS T32 DK007180
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort.

methodsPatients with cirrhosis without a history of HCC were recruited between May 2015 and March 2020 and prospectively followed at 3 tertiary care hospitals in Los Angeles. Microbiome analysis was performed on duodenal biopsies and metabolomic analysis was performed on serum samples, collected at the time of enrollment. Optimal microbiome-based survival analysis and Cox proportional hazards regression analysis were used to determine microbiota and metabolite associations with HCC development, respectively.

resultsA total of 227 participants with liver cirrhosis contributed a total of 459.58 person-years of follow-up, with 14 incident HCC diagnoses. Male sex (HR = 7.06, 95% CI = 1.02-54.86) and baseline hepatic encephalopathy (HE, HR = 4.65, 95% CI = 1.60-13.52) were associated with developing HCC over follow-up. Adjusting for age, sex, baseline HE, and alkaline phosphatase, an increased risk of HCC were observed for participants with the highest versus lowest three quartiles for duodenal Alloprevotella (HR = 3.22, 95% CI = 1.06-9.73) and serum taurocholic acid (HR = 6.87, 95% CI = 2.32-20.27), methionine (HR = 9.97, 95% CI = 3.02-32.94), and methioninesulfoxide (HR = 5.60, 95% CI = 1.84-17.10). Being in the highest quartile for Alloprevotella or methionine had a sensitivity and specificity for developing HCC of 85.71% and 60.56%, respectively, with an odds ratio of 10.92 (95% CI = 2.23-53.48).

conclusionAlloprevotella and methionine, methioninesulfoxide, and taurocholic acid predicted future HCC development in a high-risk population of participants with liver cirrhosis.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicrobiotaHumansLiver CirrhosisMaleMethionineProportional Hazards ModelsProspective StudiesRisk FactorsTaurocholic AcidMethionineTaurocholic AcidAlloprevotellaBile acidsBiogenic aminesMethionineSmall intestineTaurocholic acidTime-to-event

Identifiers

PMID34799768
PMCPMC9287237
OpenAlexW3214687279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.